LAG3 and cancer: An Fc-attenuated LAG-3-TCR bispecific antibody has been engineered to suppress T cell activity independently of MHC-II, demonstrating therapeutic potential in autoimmune models and offering a new avenue for sustaining T-cell function in cancer immunotherapy (191).